The clinical trial for sodium phenylbutyrate in pediatric subjects with spinal muscular atrophy (SMA) types II and III was aimed at establishing the maximum tolerated dose and assessing its impact on SMN mRNA and protein levels. The trial was terminated due to poor compliance with the study drug administration, which raises concerns about patient adherence and the feasibility of future studies. The SMA market is competitive, with existing therapies such as Spinraza (nusinersen) and Zolgensma (onasemnogene abeparvovec) already approved. This trial's failure to establish a tolerable dose may limit sodium phenylbutyrate's potential as a viable treatment option, necessitating further investigation into patient engagement strategies and alternative dosing regimens. The implications for investors and stakeholders include a reassessment of the asset's viability and potential market positioning against established therapies.